The phase of perovskite evolves when the non-stoichiometric mixed halide precursor is baked at different temperatures. Nb-doped TiO2nanorods are superior to plain nanorods as electron transport medium in crystallized perovskite.
All-inorganic
cesium lead-halide perovskites exhibit a great development
prospect in optoelectronic devices owing to their stability and remarkable
optoelectronic properties. Herein, we investigate the solution-processed
synthesis of perovskite CsPb2Br5 nanosheets
by using aqueous and ethanol as solvents. The results show that the
aqueous environment ensures the phase formation of CsPb2Br5 and that the supersaturated solution in ethanol boosts
nucleation of the nanosheets. The substrate temperature is the key
factor for the evolution of morphology and the variation of the thickness
of CsPb2Br5 nanosheets. Lower substrate temperature
(<35 °C) is conducive to the formation of evenly distributed
nanosheets with less stacking. The spatial and time-resolved fluorescence
spectra indicate the heterogeneity of the defect density and the recombination
process in different nanosheet regions. The photodetector based on
the prepared CsPb2Br5 nanosheet displays an
excellent switching current ratio (9 × 102), a short
rise and decay time (43 and 83 ms, respectively), and good stability
(75% of the initial current after 90 days in air). In addition, the
mechanical stability and flexibility of the photodetector on the flexible
substrate are investigated for 500 bending cycles.
Previous studies have shown that hepatitis B core antibody (anti-HBc) levels vary during different phases of disease in treatment-naïve chronic hepatitis B (CHB) patients and can be used as a predictor of both interferon-α and nucleoside analogue therapy response. However, there is no information on the association between the quantitative serum anti-HBc (qAnti-HBc) level and liver inflammation in CHB patients. Therefore, we investigated these relationships in a large cohort of treatment-naïve CHB patients. A total of 624 treatment-naïve CHB patients were included in the study. The serum qAnti-HBc level was moderately correlated with ALT and AST levels (P < 0.001) in both hepatitis B e antigen-positive (HBeAg [+]) and HBeAg-negative (HBeAg [−]) CHB patients. CHB patients with no to mild inflammation (G0–1) had significantly lower serum qAnti-HBc levels than patients with moderate to severe inflammation (G2–4) (P < 0.001). Receiver operating characteristic analysis suggested that a serum qAnti-HBc cut-off value of 4.36 log10 IU/mL provided a sensitivity of 71.68%, specificity of 73.81%, positive predictive value of 78.43%, and negative predictive value of 66.24% in HBeAg (+) CHB patients with moderate to severe inflammation (G≥2). A cut-off value of 4.62 log10 IU/mL provided a sensitivity of 54.29%, specificity of 90.00%, positive predictive value of 95.00%, and negative predictive value of 36.00% in HBeAg (−) CHB patients with moderate to severe inflammation (G≥2). Serum qAnti-HBc levels were positively associated with liver inflammation grade. Furthermore, we identified optimal serum qAnti-HBc cut-off values for the prediction of inflammation activity in both HBeAg (+) and HBeAg (−) treatment-naïve CHB patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.